VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZEPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ZEPPZepp Health Corporation
$4.96$5M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ZEPP
  4. Financial Ratios

Zepp Health Corporation (ZEPP) Financial Ratios

Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -16.8%. (2015–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ZEPP Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$5M$27M$42M$86M$89M$334M$771M$777M$553M——
Enterprise Value$123M$832M$563M$478M$832M$173M$-772027357$-898010083$-861791199——
P/E Ratio →-0.12————15.4221.941.344.84——
P/S Ratio0.020.010.030.030.020.050.130.130.15——
P/B Ratio0.020.020.020.030.030.110.280.310.31——
P/FCF———2.11——10.741.900.79——
P/OCF———2.03——5.121.750.77——

P/E links to full P/E history page with 30-year chart

ZEPP EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—0.460.420.190.200.03-0.13-0.15-0.23——
EV / EBITDA—————1.21-4.06-1.41-2.23——
EV / EBIT—————1.16-3.07-1.38-2.15——
EV / FCF———11.68——-10.75-2.19-1.23——

ZEPP Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin39.2%39.2%38.5%26.2%19.4%20.9%20.7%25.3%25.8%24.1%17.7%
Operating Margin-11.3%-11.3%-25.9%-8.6%-9.9%1.5%2.7%10.7%10.0%8.9%0.9%
Net Profit Margin-15.5%-15.5%-41.6%-8.8%-7.0%2.2%3.6%9.9%9.3%8.2%1.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-16.8%-16.8%-25.5%-8.6%-10.5%4.8%8.3%26.8%29.5%35.4%8.5%
ROA-7.2%-7.2%-13.3%-4.5%-5.2%2.3%3.9%13.7%14.9%13.3%3.3%
ROIC-6.6%-6.6%-9.8%-5.1%-10.2%3.5%12.5%77.8%88.4%60.0%9.3%
ROCE-9.4%-9.4%-11.8%-6.2%-11.2%2.6%5.7%27.3%30.8%38.0%4.7%

ZEPP Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.061.060.720.550.640.460.270.040.020.070.04
Debt / EBITDA—————9.363.820.170.100.210.77
Net Debt / Equity—0.540.280.160.28-0.05-0.57-0.68-0.78-0.58-0.42
Net Debt / EBITDA—————-1.11-8.11-2.63-3.66-1.86-8.65
Debt / FCF———9.57——-21.50-4.09-2.01-1.61-31.53
Interest Coverage-5.59-5.59-9.43-4.13-5.543.38—————

ZEPP Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.021.021.292.041.771.831.731.772.061.461.36
Quick Ratio0.770.771.001.491.161.241.291.411.701.171.05
Cash Ratio0.390.390.570.940.600.710.820.731.150.440.26
Asset Turnover—0.460.350.550.811.011.031.131.161.351.67
Inventory Turnover2.172.171.983.073.373.893.974.895.705.886.92
Days Sales Outstanding—103.45158.1284.8674.2764.2976.65103.6673.10118.51111.83

ZEPP Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield————7.1%——0.6%———
Payout Ratio———————0.8%———

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield—————6.5%4.6%74.5%20.7%——
FCF Yield———47.4%——9.3%52.7%127.2%——
Buyback Yield25.9%32.3%5.4%2.9%9.1%4.1%0.0%0.0%1.5%——
Total Shareholder Yield25.9%32.3%5.4%2.9%16.2%4.1%0.0%0.6%1.5%——
Shares Outstanding—$993873$16M$15M$15M$17M$16M$16M$14M$15M$15M

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Unsustainable Cash Burn Rate

Market Skepticism Reflects Hardware Commodity

According to current market data, Zepp trades at a P/S ratio of 0.02, a valuation multiple that suggests investors are heavily discounting the company's future earnings potential and viewing its hardware-centric business model as a commoditized manufacturing play rather than a high-growth health technology platform.

The forward P/E of 64.23 implies that the market is pricing in a significant, albeit uncertain, recovery in profitability that has yet to materialize in the income statement. This valuation gap relative to premium peers like Garmin indicates that the market requires tangible evidence of successful brand-led monetization before re-rating the stock.

Capital Efficiency Decaying Amid Pivot

Based on reported financial figures, Zepp's ROIC has trended into negative territory, reaching -1.0% in 2025Q4, which highlights the company's struggle to generate positive returns on its invested capital while simultaneously funding an aggressive and costly transition toward a self-branded wearable ecosystem.

The consistent decline in return metrics suggests that the capital deployed into R&D and global marketing is not currently yielding the expected operational efficiencies. Investors should monitor whether this decay is a temporary byproduct of the rebranding phase or a structural issue with the company's ability to scale its proprietary technology.

Working Capital Inefficiencies Hamper Liquidity

As reported in recent quarterly filings, Zepp's cash conversion cycle has shifted significantly, with inventory turnover days reaching 148 in 2025Q4, suggesting that the company is facing mounting challenges in managing its hardware supply chain and clearing older product models in a highly competitive market.

The widening gap between DSO and DPO indicates that the company is losing leverage with its suppliers while simultaneously struggling to collect on its receivables efficiently. This deterioration in working capital management is a primary driver of the current cash burn and warrants close scrutiny in future periods.

Liquidity Buffer Narrows Under Pressure

According to the latest balance sheet data, Zepp's current ratio has tightened to 1.02, a level that leaves the company with a precarious margin of safety to navigate short-term operational volatility or unexpected disruptions in its global consumer electronics supply chain and distribution networks.

The decline in the quick ratio to 0.77 further underscores the company's reliance on inventory liquidity, which may be overstated if older models require significant markdowns. This liquidity profile suggests that the company's ability to sustain its current burn rate is becoming increasingly dependent on its remaining cash reserves.

Misapplied Focus on Revenue Growth

Investors frequently misapply the revenue growth metric to Zepp, failing to recognize that in a hardware-heavy transition phase, top-line expansion often masks the underlying erosion of margins and the increasing cost of acquiring market share in a saturated global wearable technology landscape.

Instead of focusing on revenue, analysts should prioritize the 'Active User Base' and 'Average Selling Price' of self-branded products to gauge the true health of the ecosystem. Relying on revenue growth alone obscures the reality that the company is currently buying market share at the expense of long-term shareholder value.

Download Financial Ratios Data

Includes 30+ ratios · 11 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ZEPP — Frequently Asked Questions

Quick answers to the most common questions about buying ZEPP stock.

What is Zepp Health Corporation's P/E ratio?

Zepp Health Corporation's current P/E ratio is -0.1x. The historical average is 10.9x.

What is Zepp Health Corporation's ROE?

Zepp Health Corporation's return on equity (ROE) is -16.8%. The historical average is 3.3%.

Is ZEPP stock overvalued?

Based on historical data, Zepp Health Corporation is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.

What are Zepp Health Corporation's profit margins?

Zepp Health Corporation has 39.2% gross margin and -11.3% operating margin.